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Can IGRA assays, used in the highly specific and sensi-
tive quantiFERON and T-spot tests, predict the develop-
ment of disease in individuals who are infected but
currently display no symptoms? High ESAT-6 reactivity
may predict disease because ESAT-6 is a marker for
bacterial burden. We found that vaccinated cattle for
which the vaccine did not offer protection displayed
high reactivity to ESAT-6 early in infection; cattle that
controlled the infection displayed low ESAT-6 reactivity.
By evaluating the response in guinea pigs both vacci-
nated and not vaccinated with BCG, we found that the
animals with a large skin test result (high reactivity)
after infection with Mycobacterium tuberculosis did not
have a long survival time. In mouse vaccination studies
ESAT-6 reactivity dropped as the vaccine controlled
bacterial activation, which indicates that ESAT-6 reactiv-
ity correlates with the dynamics of infection.
For humans, we developed a template to use as a cut-
off or conversion model for predicting three possible
scenarios for individuals post-exposure. The model,
based on IFN-g levels in response to ESAT-6, delineates
three possible reactions: people who control initial bac-
terial replication and remain ESAT-6 negative; people
who fail to control initial replication, but eventually con-
trol the infection, becoming ESAT-6 positive and
latently infected; people who fail to control replication,
become ESAT-6 positive and later develop clinical TB.
A large study with serial quantitative IGRA testing is
necessary to be able to make a statistically robust ROC
curve.
ESAT-6/CFP10 has great value as a predictor of TB
disease. In low/meso-endemic regions, ESAT-6/CFP10
predicts progression to disease with higher accuracy
than PPD, resulting in more precise targeting, preventive
therapy and less treatment. In high endemic regions, the
potential for TB prediction may depend on the estab-
lishment of a cut-off or QFT conversion that would
allow the identification of QFT positive individuals at
the highest risk of progression. If longitudinal monitor-
ing of ESAT-6 reactivity levels is used as a biomarker of
bacterial replication, it can also be useful as a clinical
endpoint, allowing for much shorter clinical trials of
both vaccines and novel drugs.
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